ArticleFrontiers in oncology2026
Preclinical identification of an oxadiazole-pyrazole lead targeting prostate cancer through integrated mechanistic evaluation.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer remains a major cause of cancer-related mortality among men, while resistance to androgen deprivation therapy emphasizes the need for new therapeutic strategies. Molecular hybridization of pharmacologically relevant heterocycles offers a rational approach for developing novel anticancer agents. Methods: Twenty oxadiazole-pyrazole hybrids (VS-01-VS-20) were designed, synthesized, and evaluated using molecular docking against the androgen receptor (PDB ID: 1Z95), followed by Results: VS-04 demonstrated a favorable interaction profile within the androgen receptor ligand-binding pocket and exhibited potent antiproliferative activity, with IC Conclusion: The integrated computational and experimental evaluation identified VS-04 as a promising oxadiazole-pyrazole lead with potent antiproliferative activity against prostate cancer cells. Its activity was associated with AR modulation, oxidative stress, cell-cycle perturbation, and apoptotic cell death, supporting further structural optimization and preclinical investigation of this scaffold for prostate cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.